tradingkey.logo

BRIEF-Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

ReutersFeb 4, 2025 2:22 PM

- Rezolute Inc RZLT.O:

  • REZOLUTE PROVIDES UPDATE ON ITS PHASE 3 SUNRIZE STUDY OF ERSODETUG FOR THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL HYPERINSULINISM

  • REZOLUTE INC - SUNRIZE ENROLLMENT COMPLETION EXPECTED IN Q2 2025

  • REZOLUTE INC - DMC REVIEWED OPEN-LABEL ARM FOR INFANTS, TARGET DRUG CONCENTRATIONS SAFELY REACHED

  • REZOLUTE INC - DMC APPROVES INFANT ENROLLMENT INTO DOUBLE-BLIND STUDY

Source text: ID:nGNX9dD3TS

Further company coverage: RZLT.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI